Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab + Pembrolizumab in Advanced Endometrial Cancer
NCT06046274Phase 2Withdrawn
- Sponsor
- Genmab
- Start
- Oct 2023
- Primary completion
- Apr 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of acasunlimab in endometrial cancer (EC), sponsored by Genmab. Planned start Oct 2023; status: withdrawn.
02
Drugs
acasunlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06046274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046274.